BioNxt Solutions Inc. SEDAR Filings

Results 2026-05-29

Open PDF

Interim MD&A - English.pdf

Results 2026-05-29

Open PDF

Interim financial statements/report – English.pdf

News 2026-05-20

Open PDF

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

News release - English.pdf

News 2026-05-20

Open PDF

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

News release - English.pdf

News 2026-05-20

Open PDF

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

News release - English.pdf

News 2026-05-20

Open PDF

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

News release - English.pdf

News 2026-05-20

Open PDF

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

News release - English.pdf

News 2026-05-20

Open PDF

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

News release - English.pdf

News 2026-05-20

Open PDF

BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

News release - English.pdf

Results 2026-04-29

Open PDF

Annual MD&A - English.pdf

Results 2026-04-29

Open PDF

Audited annual financial statements – English.pdf

Transactions 2026-02-27 Financing

Open PDF

BIONXT ANNOUNCES CLOSING OF SHARES FOR DEBT SETTLEMENT

News release - English.pdf

Transactions 2026-01-23 Financing

Open PDF

BioNxt Solutions Inc. Announces Shares for Debt Settlement

News release - English.pdf

Results 2026-01-21

Open PDF

BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment of Multiple Sclerosis (MS)

News release - English.pdf

News 2026-01-20

Open PDF

BioNxt Solutions Inc. Announces Significant Progress in Mission to Address Swallowing Difficulties with Rapid-Dissolving Thin-Film Therapies and Secures First National-Level Patent

News release - English.pdf

Results 2026-01-20

Open PDF

BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF

News release - English.pdf

News 2025-12-17

Open PDF

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the Eurasian Patent Organization (EAPO) has officially granted Patent No. 051510 (issued November 14, 2025).

News release - English.pdf

Transactions 2025-12-17 M&A

Open PDF

BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments

News release - English.pdf

News 2025-12-17

Open PDF

BioNxt Advances “Melt in Your Mouth” Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia

News release - English.pdf

Results 2025-11-28 Financials

Open PDF

Interim financial statements/report – English.pdf

Results 2025-11-28 Financials

Open PDF

Interim MD&A - English.pdf

News 2025-11-04